Imagine a world where Alzheimer’s disease, the leading cause of death in Australia, could be tackled with a revolutionary approach. That’s exactly what Evinco Therapeutics, a bold new biotech spin-out from Cartherics, aims to do. Launched in Melbourne on December 8, 2025, under the leadership of Professor Alan Trounson AO, Evinco is on a mission to transform the treatment landscape for Alzheimer’s and other neuroinflammatory conditions. But here’s where it gets groundbreaking: their focus is on harnessing the power of Extracellular Vesicles (EVs) derived from Natural Killer (NK) cells—a strategy that could redefine how we approach neurodegenerative diseases.
Professor Trounson, CEO and Executive Chair, highlights the serendipitous discovery that sparked this venture: “We’ve found that tiny EVs extracted from NK cells have remarkable effects on microglia, the brain’s immune cells. This could open a new frontier in the fight against Alzheimer’s and similar conditions.” These NK-EVs are designed for intranasal delivery, a simple yet innovative method to target affected brain areas directly. And this is the part most people miss—this approach not only holds promise for Alzheimer’s but also for other neurological disorders, potentially addressing a global market projected to reach USD $17 billion by 2033.
But here’s the controversial part: Can a therapy originally explored for cancer and endometriosis truly revolutionize Alzheimer’s treatment? Evinco’s spin-out from Cartherics allows both companies to specialize—Cartherics on its core programs, and Evinco on this cutting-edge immune-based therapy. Supported by a world-class team of scientists, leaders, and collaborators from top academic and medical institutions, Evinco is poised to accelerate research into tangible therapies. Their proof-of-concept studies, funded by ongoing capital raises, aim to validate this novel approach, offering hope in the face of rising dementia rates.
As Evinco sets new benchmarks for innovation and patient outcomes, one question lingers: Could this be the breakthrough we’ve been waiting for? What do you think—is this the future of Alzheimer’s treatment, or is there still too much uncertainty? Share your thoughts in the comments below and join the conversation. For more details, visit Evinco’s official announcement.
